Early intervention with psychostimulants or antidepressants to increase methyl-CpG-binding protein 2 (MeCP2) expressions: A potential therapy for Rett syndrome

Medical Science Monitor

Volumn 18, Issue 1, 2012, Pages

  Pan, Chia Ho ^a   Tsai, Shih Jen ^b,c  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Antidepressants; Methyl CpG binding protein 2 (MeCP2); Psychostimulants; Rett syndrome; Treatment; X chromosome inactivation

Indexed keywords

COCAINE; DESIPRAMINE; FLUOXETINE; METHYL CPG BINDING PROTEIN 2;

ARTICLE; DISEASE SEVERITY; GENE EXPRESSION; GENE MUTATION; HUMAN; NONHUMAN; PROTEIN EXPRESSION; RETT SYNDROME;

EID: 84855292340     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.882183     Document Type: Article

References (19)

1. Amir RE, Van den Veyver IB, Wan M et al: Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet, 1999; 23: 185-88
2. Segawa M, Nomura Y: Rett syndrome. Curr Opin Neurol, 2005; 18: 97-104
3. Segawa M: Pathophysiology of Rett syndrome from the standpoint of clinical characteristics. Brain Dev, 2001; 23(Suppl.1): S94-98
4. Panayotis N, Ghata A, Villard L, Roux JC: Biogenic amines and their metabolites are differentially affected in the Mecp2-deficient mouse brain. BMC Neurosci, 2011; 12: 47
5. Nomura Y, Segawa M: Natural history of Rett syndrome. J Child Neurol, 2005; 20: 764-68
6. Guy J, Gan J, Selfridge J et al: Reversal of neurological defects in a mouse model of Rett syndrome. Science, 2007; 315: 1143-47
7. Guy J, Hendrich B, Holmes M et al: A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet, 2001; 27: 322-26
8. Auranen M, Vanhala R, Vosman M et al: MECP2 gene analysis in classical Rett syndrome and in patients with Rett-like features. Neurology, 2001; 56: 611-17
9. Chahrour M, Zoghbi HY: The story of Rett syndrome: from clinic to neurobiology. Neuron, 2007; 56: 422-37
10. Smeets E, Schollen E, Moog U et al: Rett syndrome in adolescent and adult females: clinical and molecular genetic findings. Am J Med Genet A, 2003; 122A: 227-33
11. Hoffbuhr KC, Moses LM, Jerdonek MA et al: Associations between MeCP2 mutations, X-chromosome inactivation, and phenotype. Ment Retard Dev Disabil Res Rev, 2002; 8: 99-105
12. Young JI, Zoghbi HY: X-chromosome inactivation patterns are unbalanced and affect the phenotypic outcome in a mouse model of rett syndrome. Am J Hum Genet, 2004; 74: 511-20
13. Cassel S, Carouge D, Gensburger C et al: Fluoxetine and cocaine in- duce the epigenetic factors MeCP2 and MBD1 in adult rat brain. Mol Pharmacol, 2006; 70: 487-92
14. Tsai SJ: Lithium and antidepressants: Potential agents for the treatment of Rett syndrome. Med Hypotheses, 2006; 67: 626-29
15. Wozniak G, Toska A, Saridi M, Mouzas O: Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis. Med Sci Monit, 2011; 17(9): 205-14
16. Zanella S, Mebarek S, Lajard AM et al: Oral treatment with desipra- mine improves breathing and life span in Rett syndrome mouse model. Respir Physiol Neurobiol, 2008; 160: 116-21
17. Roux JC, Dura E, Moncla A et al: Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. Eur J Neurosci, 2007; 25: 1915-22
18. Kerr AM, Montague J, Stephenson JB: The hands, and the mind, pre- and post-regression, in Rett syndrome. Brain Dev, 1987; 9: 487-90
19. Krepischi AC, Kok F, Otto PG: X chromosome-inactivation patterns in patients with Rett syndrome. Hum Genet, 1998; 102: 319-21